-
Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer
Time of Update: 2020-07-14
Whether angiokine -strain conversion enzyme (ACE) inhibitors and angiotensin receptor blockers will alter the risk of colorectal cancer remains debatable In a recent study published in the 's author
-
Mol. Pharmaceutics: Canadian scientists develop new method to deliver cancer drugs accurately to tumors
Time of Update: 2020-07-14
Today, colorectal cancer a common type of cancer, with the highest incidence and fatality rates in the world, with nearly 2 million new cases and nearly 900,000 deaths in 2018 alone In China, the
-
PD-L1 single-resistant Bavencio, FDA approved for maintenance treatment for patients with late or metastatic urethra skin cancer
Time of Update: 2020-07-14
Merck and Pfizer announced that the U.S Food and Drug administration ( FDA ) has expanded its application range for the maintenance of local late or metastatic urinary tract cancer (UC) patients
-
PNAS: New breakthrough: Blocking a protein to suppress liver and bile duct cancer
Time of Update: 2020-07-14
Liver cancer is one of the most common digestive cancerinopathic cancer in China, about 110,000 people die of liver cancer every year, accounting for 45% of the world's liver cancer deaths Bile du
-
Tisotumab Vedotin Treatment for Recurrent or Metastatic Cervical Cancer: Positive Results in Phase II Clinical Trials
Time of Update: 2020-07-14
The objective response rate to standard treatment in patients with recurrent or metastatic cervical cancer is usually less than 15%, with a median total survival of between 6.0 and 9.4 months Seattl
-
FDA approves oral drug for blood cancer - Low Methylation Agent Inqovi
Time of Update: 2020-07-14
Otsuka Pharmaceuticals inc announces the approval of Inqovi (decitabine/cedazuridine inhibitors/titabinin), for the treatment of myelogenmic abnormal syndrome (MDS) and chronic granulocytic mononucl
-
Focusing on the nutritional status of cancer patients: malnutrition seriously affects tumor prognosis
Time of Update: 2020-07-14
Global cancer mortality rates have remained high over the past half century According to the WHO Global Cancer Statistics Report, there were 18.1 million new cases of cancer worldwide and 9.6 millio
-
Antibody drug conjugate DS-1062 study expanded to treat triple-negative breast cancer patients
Time of Update: 2020-07-14
The First Three announced that its antibody drug Couple (ADC), which targets TROP2, is being evaluated for safety, tolerance and initial efficacy in patients with advanced non-removable or metastati
-
Professor Cao Wei: Avapritinib Drug-resistant Mutation, GIST Patient Treatment To a New Heights
Time of Update: 2020-07-14
Gastrointestinal mesoplinoma (GIST) is mainly caused by GENE mutations driven by KIT and PDGFRA, and surgery is a fundamental treatment for limited GIST GIST is insensitive to chemotherapy, and Ima
-
A list of recent important research progress on leukemia
Time of Update: 2020-07-14
1 Genetic-transcriptiography analysis identified the key transcription factor as the driver of human red leukemia acute erytic leukemia (AML-M6 or AEL) is a rare invasive blood tumor Previou
-
Cancer Sci: Pembrolizumab monototherapy in patients with advanced ovarian cancer in Japan
Time of Update: 2020-07-14
Interim results of the 2-phase KEYNOTE-100 study (NCT02674061) of 376 patients with advanced recurrent ovarian cancer (ROC) in the past showed that the Bloomberg Zuma single drug treatment was ass
-
First anti-PAUF single anti-PBP1510 treatment for pancreatic cancer, awarded the title of orphan drug by the FDA
Time of Update: 2020-07-14
Prestige BioPharma announced that the U.S Food and Drug Administration( FDA ) has awarded orphan drug drugs (ODD) for its -up factor (PAUF) monoclonal antibody PBP1510 for the treatment of pancr
-
Hypertension: Review of cohort study: Common hypertension drugs may reduce risk of colorectal cancer
Time of Update: 2020-07-14
Drugs commonly used to treat high blood pressure also reduce the risk of colorectal cancer , according to a new study published July 5 in the Journal of the American Heart Association drugs such
-
FDA approves FGF23 blocking antibody Crysvita for tumor-induced osteosesasapha (TIO)
Time of Update: 2020-07-14
Ultragenyx Pharmaceuticals and Kyowa Kirin inc announced that the U.S Food and Drug Administration Administration ( FDA ) has approved its fibroblast growth factor 23 (FGF23) blocking antibody Cry
-
Clini Cancer Research: Total transcriptomic sequencing analysis of tumor tissue after Hu14.18-IL2 immunotherapy identification of prognostic biomarkers
Time of Update: 2020-07-14
Objective: Richard K Yang et al analyzed the whole transcriptomic sequencing data of tumors in 23 stage III-IV melanoma patients in a pilot trial of the anti-GD2 immunoastic factor hu14.18-IL2 to
-
Professor Wu Gaosong: Progress in Breast Cancer Surgery and Systemic Treatment
Time of Update: 2020-07-14
Breast cancer is a common and high-risk tumor in Chinese women In recent years, the systematic treatment of breast cancer has made great progress, at the same time, surgical treatment in the treatm
-
Roche's PD-L1 monoanti-Tecentriq shows hope in early triple-negative breast cancer
Time of Update: 2020-07-14
Roche's PD-L1 monoantitic Tecentriq (atezolizumab) has been used in conjunction with chemotherapy to improve the treatment of patients with early triple-negative breast cancer (TNBC), offering new
-
Eur J Cancer: HOXA9 meth-ctDNA acts as biomarker for BRCA mutant ovarian cancer
Time of Update: 2020-07-14
Poly (ADP-ribose) polymerase (PARP) inhibitors have become a new treatment option for BRCA mutations ovarian cancer (OC); Therefore, we studied whether homeobox A9 (HOXA9) promoter methylation in
-
JCO: Obesity is a delay again! Large retrospective analysis showed that chemotherapy was poor in obese breast cancer patients.
Time of Update: 2020-07-14
How harmful is obesity? In the case of breast cancer , the higher the BMI and the higher the risk of breast cancer in the Asian population before diagnosis, and after diagnosis, for every 5 kg of w
-
China Anti-Cancer Association's latest impact factors in three English-language journals released
Time of Update: 2020-07-14
June 29, 2020, the global professional information and analysis service Corey Weian released the 2019 Journal Report (Journal Reports Citation, or JCR), the China Anti-Cancer Association 3 of the